Your browser doesn't support javascript.
loading
PD-L1 (CD274) promoter hypomethylation predicts immunotherapy response in metastatic urothelial carcinoma.
Klümper, Niklas; Wüst, Lennert; Saal, Jonas; Ralser, Damian J; Zarbl, Romina; Jarczyk, Jonas; Breyer, Johannes; Sikic, Danijel; Wullich, Bernd; Bolenz, Christian; Roghmann, Florian; Hölzel, Michael; Ritter, Manuel; Strieth, Sebastian; Hartmann, Arndt; Erben, Philipp; Wirtz, Ralph M; Landsberg, Jennifer; Dietrich, Dimo; Eckstein, Markus.
Afiliação
  • Klümper N; Department of Urology and Pediatric Urology, University Medical Center Bonn (UKB), Bonn, Germany.
  • Wüst L; Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.
  • Saal J; Center for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
  • Ralser DJ; Center for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
  • Zarbl R; Department of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany.
  • Jarczyk J; Center for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
  • Breyer J; Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Medical Center Bonn (UKB), Bonn, Germany.
  • Sikic D; Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany.
  • Wullich B; Center for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
  • Bolenz C; Department of Gynaecology and Gynaecological Oncology, University Medical Center Bonn (UKB), Bonn, Germany.
  • Roghmann F; Center for Integrated Oncology, Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Germany.
  • Hölzel M; Department of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany.
  • Ritter M; Department of Urology and Urosurgery, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
  • Strieth S; Department of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg, Germany.
  • Hartmann A; Center for Integrated Oncology, Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.
  • Erben P; Center for Integrated Oncology, Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.
  • Wirtz RM; Center for Integrated Oncology, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
  • Landsberg J; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany.
  • Dietrich D; Center for Integrated Oncology, Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany.
  • Eckstein M; Center for Integrated Oncology, Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Oncoimmunology ; 12(1): 2267744, 2023.
Article em En | MEDLINE | ID: mdl-37868689
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Regiões Promotoras Genéticas / Imunoterapia Limite: Humans Idioma: En Revista: Oncoimmunology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Bexiga Urinária / Carcinoma de Células de Transição / Regiões Promotoras Genéticas / Imunoterapia Limite: Humans Idioma: En Revista: Oncoimmunology Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Alemanha